# Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

> **NCT01729806** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 32 (actual)

## Conditions studied

- CD20 Positive
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01729806
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-19
- **Primary completion:** 2018-03-30
- **Final completion:** 2018-03-30
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01729806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01729806, "Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01729806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*